2 results
Approved WMOCompleted
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
Approved WMOCompleted
Primary* To evaluate safety and tolerability of LNP3794 at selected dose levelsSecondary* To determine the therapeutic relevant dose(s) of LNP3794* To describe the PK profile of LNP3794 following single and multiple oral administrationOther* To…